A. Li - Publications, H-index & Citations

A. Li

north china electric power university

8H指数

23论文数

701被引数

收录论文 9

发表时间

Analysis of the effect of LFR bending fuel assembly on thermal-hydraulic characteristics LFR弯曲燃料组件对热工水力特性的影响分析

ANNALS OF NUCLEAR ENERGY

IF2.3

2025-10-01

PREAI

Sun, JiTong; Huang, Mei; Li, YaoDi; Li, Aonan; Cheng, YanTing

Bayberry extract-supplemented fermented milk exert anti-inflammatory benefits in C57/BL6 mice with DSS-induced ulcerative colitis 杨梅提取物补充的发酵乳在DSS诱导的溃疡性结肠炎C57/BL6小鼠中发挥抗炎益处

Food Bioscience

IF5.9

2025-07-14

PREAI

Yi Liang; Aoxiang Li; Zhenzhen Wang; Ruonan Ni; Xinyu Chen; Shaoman Guo; Ying Cheng; Yueliang Zhao; Jingya Yang

HANDSON Hand: Strategies and Approaches for Competitive Success at CYBATHLON 2024

BIOENGINEERING-BASEL

IF3.7

2025-02-24

OAAI

Hu, Xuhui; Guo, Fengkai; Wei, Zhikai; Chen, Dapeng; Dai, Junfa; Li, Anran; Zhang, Senhao; Orban, Mostafa; Tong, Yao; Hu, Cong; Xu, Baoguo; Zeng, Hong; Song, Aiguo; Guo, Kai; Yang, Hongbo

Calcineurin inhibitors or cyclophosphamide in the treatment of membranous nephropathy superimposed with FSGS lesions: a retrospective study from China

RENAL FAILURE

IF3

2023-09-19

OAAI

He, Hong-Guang; Huang, Yi-Yun; Liang, Qin-Qing; Ye, Qiu-Rong; Li, An-Dong; Ye, Kun; Wu, Qiu-Xia; You, Yan-Wu

Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term results

ANNALS OF ONCOLOGY

IF65.4

2022-04-01

OAAI

Lu, S.; Cheng, Y.; Zhou, J.; Wang, M.; Zhao, J.; Wang, B.; Chen, G.; Feng, J.; Ma, Z.; Wu, L.; Wang, C.; Ma, K.; Zhang, S.; Liang, J.; Song, Y.; Wang, J.; Wu, Y-L.; Li, A.; Huang, Y.; Chang, J.

Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1

ANNALS OF ONCOLOGY

IF65.4

2020-12-01

OAAI

Brahmer, J. R.; Ciuleanu, T-E.; Schenker, M.; Audigier-Valette, C.; Zurawski, B.; Linardou, H.; Kim, S-W.; Otterson, G. A.; Salman, P.; De La Mora Jimenez, E.; Lesniewski-Kmak, K.; Ahmed, S.; Albert, I.; Barlesi, F.; Feeney, K.; Frickhofen, N.; Li, A.; Sun, P.; Hellmann, M.

First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) plus chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA

ANNALS OF ONCOLOGY

IF65.4

2020-09-01

OAAI

John, T.; Sakai, H.; Ikeda, S.; Cheng, Y.; Kasahara, K.; Sato, Y.; Nakahara, Y.; Takeda, M.; Kaneda, H.; Zhang, H.; Maemondo, M.; Minato, K.; Hisada, T.; Misumi, Y.; Satouchi, M.; Hotta, K.; Li, A.; Oukessou, A.; Lu, S.

CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC)

ANNALS OF ONCOLOGY

IF65.4

2020-09-01

OAAI

De Ruysscher, D.; Ramalingam, S. S.; Urbanic, J.; Gerber, D. E.; Tan, D. S. W.; Cai, J.; Li, A.; Peters, S.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

ANNALS OF ONCOLOGY

IF65.4

2018-04-01

399

OAAI

Vokes, E. E.; Ready, N.; Felip, E.; Horn, L.; Burgio, M. A.; Antonia, S. J.; Frontera, O. Aren; Gettinger, S.; Holgado, E.; Spigel, D.; Waterhouse, D.; Domine, M.; Garassinoio, M.; Chow, L. Q. M.; Blumenschein, G., Jr.; Barlesi, F.; Coudert, B.; Gainor, J.; Arrieta, O.; Brahmer, J.; Butts, C.; Steins, M.; Geese, W. J.; Li, A.; Healey, D.; Crino, L.

研究方向